C12N 5/0634
Cells from the blood or the immune system
Official title: {Cells from the blood or the immune system}
C12N5/0634 (Cells from the blood or the immune system) appears on 6,272 US grants and 13,748 published applications in this corpus.
Search patents in C12N- Granted patents
- 6,272
- Published applications
- 13,748
- Assignees
- 3,458
- Inventors
- 18,534
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 1 | 0 |
| 1980 | 2 | 0 |
| 1981 | 0 | 0 |
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 2 | 0 |
| 1985 | 2 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 2 | 0 |
| 1989 | 4 | 0 |
| 1990 | 1 | 0 |
| 1991 | 3 | 0 |
| 1992 | 7 | 0 |
| 1993 | 12 | 0 |
| 1994 | 14 | 0 |
| 1995 | 19 | 0 |
| 1996 | 18 | 0 |
| 1997 | 39 | 0 |
| 1998 | 62 | 0 |
| 1999 | 53 | 0 |
| 2000 | 43 | 0 |
| 2001 | 59 | 29 |
| 2002 | 51 | 128 |
| 2003 | 57 | 150 |
| 2004 | 37 | 169 |
| 2005 | 41 | 160 |
| 2006 | 44 | 158 |
| 2007 | 28 | 142 |
| 2008 | 47 | 143 |
| 2009 | 62 | 179 |
| 2010 | 88 | 248 |
| 2011 | 100 | 268 |
| 2012 | 99 | 225 |
| 2013 | 124 | 251 |
| 2014 | 160 | 296 |
| 2015 | 181 | 344 |
| 2016 | 205 | 408 |
| 2017 | 217 | 538 |
| 2018 | 312 | 708 |
| 2019 | 394 | 972 |
| 2020 | 497 | 1059 |
| 2021 | 517 | 1218 |
| 2022 | 502 | 1373 |
| 2023 | 489 | 1231 |
| 2024 | 602 | 1323 |
| 2025 | 636 | 1161 |
| 2026 | 435 | 867 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Engineered cells and uses thereof6 Oct 2026US 12,751,929 B2Ohio State Innovation Foundation
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Inducible chimeric antigen receptor and application thereof6 Oct 2026US 12,752,007 B2Beijing Tiantan Hospital, Capital Medical University
- CCR4 targeted chimeric antigen receptor modified T cells for treatment of CCR4 positive malignancies6 Oct 2026US 12,753,219 B2City of Hope
- Intranasal delivery of cd34+ cells for the treatment of stroke8 Oct 2026US 2026/0306537 A1Cellprothera
- Application of CCR5hi Innate Immune Memory Cells in Preparation of Immunotherapeutic Drug for Treating Sepsis8 Oct 2026US 2026/0306538 A1Children's Hospital of Soochow University
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Novel phosphoantigen prodrug compound and use thereof8 Oct 2026US 2026/0306541 A1
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
Most cited
By later US patents
- Handheld electromechanical surgical system627US 10,932,784 B2Covidien LP · 2021
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Methods for selectively stimulating proliferation of T cells452US 6,534,055 B1Genetics Institute, Inc. · 2003
- Simultaneous stimulation and concentration of cells422US 6,797,514 B2XCYTE Therapies, Inc. · 2004
- Simultaneous stimulation and concentration of cells398US 6,867,041 B2XCYTE Therapies, Inc. · 2005